WWRL yields 21505.38% · ABBV yields 3.06%● Live data
📍 WWRL pulled ahead of the other in Year 1
Combined, WWRL + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of WWRL + ABBV for your $10,000?
World Wireless Communications, Inc. engages in the design and development of wired and wireless telemetry and remote control systems. Its products and services allow data from remote devices to be accessed via a secure, encrypted Internet connection using a standard Web browser in automatic meter reading and facilities management fields. The company operates through the X-traWeb products and Radio product segments. It offers X-Node, a micro-controller, which collects, processes, and transmits information to provide wired or wireless Internet access; and X-Gate product, which serves as a data collecting and transmitting system on a wired or wireless basis through the Internet to a Web and data-hosting server. The company also provides a line of 900 MHz spread spectrum radios, including the 900 SS Hopper, a frequency hopping spread spectrum radio that offers communication in various environments; and 900 SS MicroHopper that provides a smaller form-factor and lower power-consumption for short-range applications. In addition, it offers the 900 SS Direct—either as a direct sequence or frequency-hopping combined transmitter and receiver for transmitting data up to 40 kilometers, line of sight. World Wireless Communications, Inc. also manufactures and sells antennas. The company maintains approximately 80 specialty antennas for use in law enforcement, marine, and custom applications. World Wireless Communications, Inc. is based in Greenwood Village, Colorado.
Full WWRL Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.